

07 Jan 2020 | News

QUOTED. 7 January 2020. Gaurav Singal.

by

Over the past year, next-generation sequencing (NGS) company Foundation Medicine has ramped up publishing research on genetic markers for cancer in peer-reviewed journals. Gaurav Singal, Foundation Medicine's chief data officer, says he's particularly proud of the company's portfolio of solid tissue and liquid biopsy assays that complement each other to help diagnose and treat cancers. Check out his comment here.

“At the end of the day, finding [a mutation] is great, but it's only important to the world if it impacts the patient's treatment decisions in a meaningful way.” – Gaurav Singal, chief data officer, Foundation Medicine Inc.

- Find out more: [Partnerships Are Key To Foundation Medicine's Success](#)

[Click here](#) for a free trial of *Medtech Insight*